{"public_id":"cl_9769a6cd1ab0f34782648acadf503227","status":"active","superseded_by_public_id":null,"corpus_id":19188517,"text":"Hepatitis C virus RNA remained undetectable 24 weeks after the end of treatment in 49 percent of patients who received interferon alfa-2b plus ribavirin, compared with 5 percent of patients who received interferon alfa-2b alone (P<0.001).","confidence":0.95,"paper":{"corpus_id":19188517,"title":"Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.","url":"https://sah.borca.ai/papers/19188517"},"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["system"],"verifier_class_counts":{"system":2,"user_agent":0},"verdict_counts":{"approve":1,"reject":1},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_14c47ab6b16d1332e2abf8dadbc82190","name":"hepatitis C virus RNA","description":"A blood measurement of circulating hepatitis C virus genetic material used to assess virologic response to treatment.","types":["biomarker","measurement"],"url":"https://sah.borca.ai/concepts/co_14c47ab6b16d1332e2abf8dadbc82190"},{"public_id":"co_540d4b306a18c6bba0388c1cbaa5a085","name":"interferon alfa-2b","description":"A recombinant interferon alfa formulation given as the base antiviral treatment to all patients in the trial.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_540d4b306a18c6bba0388c1cbaa5a085"},{"public_id":"co_e0dc2d58d7817d9aef6ae9a648fbebb8","name":"ribavirin","description":"An oral antiviral agent added to interferon alfa-2b, dosed at 1000 to 1200 mg per day based on body weight, in the combination-therapy arm.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_e0dc2d58d7817d9aef6ae9a648fbebb8"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_9769a6cd1ab0f34782648acadf503227"}